A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Status: Active_not_recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• A diagnosis of GPP or EP prior to the screening visit.
• Candidate for phototherapy or systemic therapy.
Locations
Other Locations
Japan
St.Luke's International Hospital
Chūō
Fukuoka University Hospital
Fukuoka
Kansai Medical University Hospital
Hirakata
Saitama Medical University Hospital
Iruma
Tokai University Hospital
Isehara
Isesaki Municipal Hospital
Isesaki
Teikyo University Hospital
Itabashi-ku
Kimitsu Chuo Hospital
Kisarazu
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu
Kobe University Hospital
Kobe
University Hospital, Kyoto Prefectural University of Medicine
Kyoto
The Jikei University Hospital
Minato-ku
Nagoya City University Hospital
Nagoya
Okayama University Hospital
Okayama
Nippon Life Hospital
Osaka
Osaka Metropolitan University Hospital
Osaka
Tokyo Medical University Hospital
Shinjuku-ku
Fujita Health University Hospital
Toyoake
Mie University Hospital
Tsu
Juntendo University Urayasu Hospital
Urayasu
Time Frame
Start Date: 2024-03-19
Completion Date: 2026-07-22
Participants
Target number of participants: 18
Treatments
Experimental: TAK-279 for Generalized Pustular Psoriasis
Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.
Experimental: TAK-279 for Erythrodermic Psoriasis
Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.
Related Therapeutic Areas
Sponsors
Leads: Takeda